RECRUITING

Verapamil for Neuroprotection in Stroke

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety of intra-arterial delivery of verapamil, a drug used to treat vasospasm (spasm of a blood vessel), and how it affects recovery from stroke. Recruitment is limited to patients that have received mechanical thrombectomy as standard of care.

Official Title

Intraarterial Verapamil for Neuroprotection in Ischemic Stroke

Quick Facts

Study Start:2017-04-20
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03347786

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Written informed consent
  2. * 18 years of age and over
  3. * Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
  4. * Candidate for mechanical thrombectomy procedure
  5. * Onset of symptoms less than 8 hours
  6. * Measurable neurologic deficit (NIHSS ≥4)
  7. * Willingness to follow up with rehabilitation therapy
  8. * Anticipated life expectancy of at least 3 months
  1. * Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
  2. * Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
  3. * Thrombocytopenia (platelet count \<75,000/mm3)
  4. * History of intolerance to verapamil
  5. * Previous functional disability (modified Rankin \> 1)
  6. * Severe stroke (NIHSS\>22)
  7. * Stuporous or comatose
  8. * Unlikely to be available for 90 day follow-up

Contacts and Locations

Study Locations (Sites)

AtlantiCare Regional Medical Center
Atlantic City, New Jersey, 08401
United States
St Mary Medical Center
Langhorne, Pennsylvania, 19047
United States
Crozer Chester Medical Center
Upland, Pennsylvania, 19013
United States

Collaborators and Investigators

Sponsor: Global Neurosciences Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-04-20
Study Completion Date2026-12

Study Record Updates

Study Start Date2017-04-20
Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

  • Ischemic Stroke